Advanced Cell Technology, Inc. , a leader in the field of regenerative medicine, today announced treatment of the first patient in patient cohort 2a, consisting of patients with better vision, in its U.S. clinical trial for Stargardt's Macular Dystrophy , a form of juvenile macular degeneration.
http://www.biospace.com/news_story.aspx?StoryID=293278&full=1
http://www.biospace.com/news_story.aspx?StoryID=293278&full=1
No comments:
Post a Comment